Akron's Oak Pharmaceuticals purchased three off-patent injectables from H. Lundbeck's U.S. subsidiary - Nembutal pentobarbital, Diuril chlorothiazide and Cogentin benzotropine mesylate

H. Lundbeck A/S

Denmark / Mid-Cap Biopharma ($1-$50 billion)

Seller

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Akorn Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Buyer

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced